COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Advanced Cancer, Ovarian Cancer, Lung Cancer
About this trial
This is an interventional treatment trial for Advanced Cancer focused on measuring TIGIT antibody, PVRIG antibody, COM701, Low Fc-effector function, Pembrolizumab
Eligibility Criteria
Key Inclusion Criteria:
- Subjects with histologically/cytologically confirmed advanced malignancy (solid tumor) who must have exhausted all available standard therapy; or not a candidate for standard therapy.
- Subject is able to provide written, informed consent before initiation of any study related procedures, and is able, in the opinion of the investigator, to comply with all the requirements of the study.
- Subject has Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
Key Exclusion Criteria:
- Prior treatment with a TIGIT inhibitor.
- Symptomatic interstitial lung disease or inflammatory pneumonitis.
- History of immune-related events that required immunotherapy treatment discontinuation.
Sites / Locations
- Florida Cancer SpecialistsRecruiting
- Massachusetts General Hospital.Recruiting
- START Midwest.Recruiting
- The Ohio State University Comprehensive Cancer Center.Recruiting
- The University of Tennessee WEST Cancer Center.Recruiting
- Mary Crowley Cancer ResearchRecruiting
- MD Anderson Cancer Center.Recruiting
- The START Center for Cancer Care.Recruiting
- Froedtert & Medical College of WisconsinRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
COM902 monotherapy dose escalation.
Dual combination (COM902 + COM701) for evaluation of safety/tolerability (both at RDFE).
COM902 monotherapy cohort expansion at RDFE.
COM902 + COM701 combination cohort expansion both at RDFE.
MSS-CRC Triplet combination (COM902 + COM701 + Pembrolizumab).
Platinum resistant ovarian cancer Triplet combination (COM902 + COM701 + Pembrolizumab).
Monotherapy dose escalation. COM902 monotherapy administered IV every 3 weeks in sequential dose escalation. Up to 7 dose escalation cohorts may be evaluated until a maximum tolerated dose or recommended dose for expansion (RDFE) is identified.
COM902 will be combined with COM701 for evaluation of safety and tolerability. All study drugs will be administered IV every 3 weeks.
COM902 monotherapy at the RDFE - in subjects with multiple myeloma. COM902 will be administered IV every 3 weeks.
COM902 + COM701 (both at the RDFE) evaluated in subjects with select tumor types who have exhausted standard of care treatment: HNSCC, CRC (MSS), NSCLC. All study drugs will be administered IV every 3 weeks.
Triplet combination of COM902 + COM701 + Pembrolizumab evaluated in subjects with MSS-CRC. All study drugs will be administered IV every 3 weeks.
Triplet combination of COM902 + COM701 + Pembrolizumab evaluated in subjects with PROC. All study drugs will be administered IV every 3 weeks.